Entera Bio Valuation
| ENTX Stock | USD 1.61 0.06 3.59% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Entera Bio shows a prevailing Real Value of $2.67 per share. The current price of the firm is $1.61. Our model computes the value of Entera Bio from reviewing the firm fundamentals such as Shares Outstanding of 36.83 M, operating margin of (71.93) %, and Shares Owned By Insiders of 19.01 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Entera Bio's valuation include:
Price Book 9.0768 | Enterprise Value 54.9 M | Enterprise Value Ebitda (1.52) | Price Sales 621.3109 | Enterprise Value Revenue 524.8205 |
Undervalued
Today
Please note that Entera Bio's price fluctuation is very risky at this time. Calculation of the real value of Entera Bio is based on 3 months time horizon. Increasing Entera Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Entera Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Entera Stock. However, Entera Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.61 | Real 2.67 | Target 6.0 | Hype 1.61 |
The intrinsic value of Entera Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Entera Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Entera Bio helps investors to forecast how Entera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Entera Bio more accurately as focusing exclusively on Entera Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Entera Bio's intrinsic value based on its ongoing forecasts of Entera Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Entera Bio's closest peers.
Entera Bio Cash |
|
Entera Valuation Trend
Analysing the historical paterns of Entera Bio's enterprise value and its market capitalization is a good way to estimate and gauge the value of Entera Bio over time and is usually enough for investors to make rational market timing decisions.
Entera Bio Total Value Analysis
Entera Bio is currently anticipated to have valuation of 54.9 M with market capitalization of 61.51 M, debt of 390 K, and cash on hands of 17.28 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Entera Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
54.9 M | 61.51 M | 390 K | 17.28 M |
Entera Bio Investor Information
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.26. Entera Bio had not issued any dividends in recent years. Based on the analysis of Entera Bio's profitability, liquidity, and operating efficiency, Entera Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Entera Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Entera Bio has an asset utilization ratio of 0.12 percent. This suggests that the Company is making $0.00119 for each dollar of assets. An increasing asset utilization means that Entera Bio is more efficient with each dollar of assets it utilizes for everyday operations.Entera Bio Ownership Allocation
Entera Bio holds a total of 36.83 Million outstanding shares. Entera Bio shows 19.01 percent of its outstanding shares held by insiders and 18.93 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Entera Bio Profitability Analysis
The company reported the previous year's revenue of 14 K. Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 33 K.About Entera Bio Valuation
Our relative valuation model uses a comparative analysis of Entera Bio. We calculate exposure to Entera Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Entera Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -56 K | -53.2 K | |
| Pretax Profit Margin | (111.00) | (105.45) | |
| Operating Profit Margin | (111.71) | (106.13) | |
| Net Loss | (112.18) | (106.57) | |
| Gross Profit Margin | 0.25 | 0.22 |
Entera Bio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 29 M |
Entera Bio Current Valuation Indicators
Valuation refers to the process of determining the present value of Entera Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Entera we look at many different elements of the entity such as Entera's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Entera Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Entera Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Entera Bio's worth.Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.